Literature DB >> 30927153

A Systematic Review and Evaluation of Clinical Practice Guidelines for Children and Youth with Disruptive Behavior: Rigor of Development and Recommendations for Use.

Brendan F Andrade1,2,3, Darren Courtney4,5, Stephanie Duda6, Madison Aitken4, Stephanie G Craig7, Peter Szatmari4,5, Joanna Henderson4,5, Kathryn Bennett6.   

Abstract

Clinical practice guidelines (CPG) provide a framework for evidence-based practice; however, few studies have assessed the methodological quality of CPGs relevant to child and youth mental health. This study was a systematic review of CPGs for the assessment, prevention and treatment of disruptive behavior, including attention-deficit hyperactivity disorder (ADHD), oppositional defiant disorder (ODD), conduct disorder (CD) and aggression in children and youth. Systematic review identified 29 CPGs meeting inclusion criteria that were appraised using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) validated tool. Twenty-two guidelines addressed ADHD, 2 CD, 1 ODD, 2 for Behavior Disorders collectively and 2 for Aggression. Among the 29 guidelines, two that were developed for ADHD (NICE 2013a; Spanish Ministry of Health, 2010) and one practice guideline developed for CD (NICE 2013b) met high quality criteria; one guideline for behavior disorders (Gorman et al. 2015), two for ADHD (AAP 2011a, b; SIGN 2009a, b, c, d, e), and two for aggression (Knapp et al. 2012; Scotto Rosato et al. 2012a, b) met minimum quality criteria. Findings from this review provide important information for clinicians and organizations who want to utilize guidelines to implement best-practice clinical services for children and youth with disruptive behavior.

Entities:  

Keywords:  ADHD; CD; Children; ODD; Practice guidelines; Youth

Year:  2019        PMID: 30927153     DOI: 10.1007/s10567-019-00292-2

Source DB:  PubMed          Journal:  Clin Child Fam Psychol Rev        ISSN: 1096-4037


  48 in total

Review 1.  Treatment of maladaptive aggression in youth: CERT guidelines II. Treatments and ongoing management.

Authors:  Nancy Scotto Rosato; Christoph U Correll; Elizabeth Pappadopulos; Alanna Chait; Stephen Crystal; Peter S Jensen
Journal:  Pediatrics       Date:  2012-05-28       Impact factor: 7.124

2.  ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents.

Authors:  Mark Wolraich; Lawrence Brown; Ronald T Brown; George DuPaul; Marian Earls; Heidi M Feldman; Theodore G Ganiats; Beth Kaplanek; Bruce Meyer; James Perrin; Karen Pierce; Michael Reiff; Martin T Stein; Susanna Visser
Journal:  Pediatrics       Date:  2011-10-16       Impact factor: 7.124

Review 3.  A systematic review of appraisal tools for clinical practice guidelines: multiple similarities and one common deficit.

Authors:  Joan Vlayen; Bert Aertgeerts; Karin Hannes; Walter Sermeus; Dirk Ramaekers
Journal:  Int J Qual Health Care       Date:  2005-03-02       Impact factor: 2.038

4.  The high costs of aggression: public expenditures resulting from conduct disorder.

Authors:  E Michael Foster; Damon E Jones
Journal:  Am J Public Health       Date:  2005-08-30       Impact factor: 9.308

Review 5.  Attention-deficit/hyperactivity disorder and comorbidity.

Authors:  T Spencer; J Biederman; T Wilens
Journal:  Pediatr Clin North Am       Date:  1999-10       Impact factor: 3.278

6.  Service utilization for lifetime mental disorders in U.S. adolescents: results of the National Comorbidity Survey-Adolescent Supplement (NCS-A).

Authors:  Kathleen Ries Merikangas; Jian-ping He; Marcy Burstein; Joel Swendsen; Shelli Avenevoli; Brady Case; Katholiki Georgiades; Leanne Heaton; Sonja Swanson; Mark Olfson
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2010-12-03       Impact factor: 8.829

Review 7.  The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 2: antipsychotics and traditional mood stabilizers.

Authors:  Tamara Pringsheim; Lauren Hirsch; David Gardner; Daniel A Gorman
Journal:  Can J Psychiatry       Date:  2015-02       Impact factor: 4.356

8.  Development of the AGREE II, part 2: assessment of validity of items and tools to support application.

Authors:  Melissa C Brouwers; Michelle E Kho; George P Browman; Jako S Burgers; Françoise Cluzeau; Gene Feder; Béatrice Fervers; Ian D Graham; Steven E Hanna; Julie Makarski
Journal:  CMAJ       Date:  2010-05-31       Impact factor: 8.262

9.  Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society and the Canadian Academy of Child and Adolescent Psychiatry.

Authors:  R Hamilton; C Gray; S A Bélanger; A E Warren; R M Gow; S Sanatani; J-M Côté; J Lougheed; J LeBlanc; S Martin; B Miles; C Mitchell; D A Gorman; M Weiss; R Schachar
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2009-11

10.  Implementing the American Academy of Pediatrics attention-deficit/hyperactivity disorder diagnostic guidelines in primary care settings.

Authors:  Laurel K Leslie; Jill Weckerly; Dena Plemmons; John Landsverk; Sarita Eastman
Journal:  Pediatrics       Date:  2004-07       Impact factor: 7.124

View more
  2 in total

1.  Hop tests and psychological PROs provide a demanding and clinician-friendly RTS assessment of patients after ACL reconstruction, a registry study.

Authors:  Ramana Piussi; Susanne Beischer; Roland Thomeé; Eric Hamrin Senorski
Journal:  BMC Sports Sci Med Rehabil       Date:  2020-05-13

2.  Appraisal of clinical practice guidelines for the management of attention deficit hyperactivity disorder (ADHD) using the AGREE II Instrument: A systematic review.

Authors:  Yasser Sami Amer; Haya Faisal Al-Joudi; Jeremy L Varnham; Fahad A Bashiri; Muddathir Hamad Hamad; Saleh M Al Salehi; Hadeel Fakhri Daghash; Turki Homod Albatti
Journal:  PLoS One       Date:  2019-07-05       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.